查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997263

生物模拟市场：按产品、交付模式、应用和最终用户划分－2026-2032年全球市场预测

Biosimulation Market by Offering, Delivery Model, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生物模拟市场价值将达到 38.9 亿美元，到 2026 年将成长到 41.5 亿美元，到 2032 年将达到 60.9 亿美元，复合年增长率为 6.61%。

主要市场统计数据
基准年 2025 38.9亿美元
预计年份：2026年 41.5亿美元
预测年份：2032年 60.9亿美元
复合年增长率 (%) 6.61%

清晰且有策略地介绍生物模拟，将其定位为促进转化决策、监管合作和营运一致性的重要跨职能工具。

生物模拟已从专门的研究工具发展成为支持药物发现、开发和监管合作决策的基础能力。这种应用将生物模拟置于更广泛的创新生态系统中，揭示了计算建模、模拟平台、合约服务和组织交付模式如何塑造转化工作流程。它还强调了演算法进步、不断扩展的生物数据集以及云端运算的融合如何促进了生物模拟对从实验室研究人员到监管审查人员等相关人员的重要性日益提升。

对技术、监管和交付模式的变革如何重塑生物模拟实践、伙伴关係和组织价值创造进行全面分析。

生物模拟领域经历了变革性的转变，其影响远不止于技术上的提升，也涵盖了组织模式、监管方法和协作生态系统。分子建模、生理药物动力学 (PBPK) 模拟和药物动力学/药效动力学 (PK/PD) 框架的进步，如今与更先进的毒性预测演算法和实验室设计模拟工具相辅相成，共同建构了一个多层次的工具包，为药物发现和开发阶段的各项活动提供支持。同时，服务交付方式也日益多元化。服务内容涵盖了从提供规模和专业知识的合约式项目，到能够维持对内部知识和专有模型策略控制的内部服务。

一份基于证据、不带任何推测性预测的评估报告，分析了到 2025 年关税趋势将如何影响生物模拟供应链、计算策略和跨境合作。

关税措施和贸易政策调整可能会对生物模拟生态系统产生连锁反应，影响硬体供应链、云端运算成本、软体许可流程以及跨境服务交付系统。在评估2025年的累积影响时，至关重要的是要认识到关税如何与高效能运算和支援大规模模拟的专用设备的采购週期相互交织，以及它们如何影响跨国合作和外包服务的成本结构。

高解析度細項分析揭示了产品、交付模式、应用重点和最终用户背景如何决定生物模拟的价值和部署管道。

细分市场分析揭示了每种产品、交付模式、应用和最终用户的不同需求和价值因素，因此需要量身定制的策略应对措施。在考虑所提供的解决方案时，市场可分为「服务」和「软体」两类。服务包括基于合约的外包以及提供独特建模专业知识和结果的内部团队。软体产品则各具特色，例如分子建模与模拟、生理药物动力学（PBPK）建模与模拟、药物动力学/药效动力学（PK/PD）建模与模拟、毒性预测和测试设计工具，每款产品都针对药物发现和开发过程的不同阶段，并需要独特的检验和整合方法。

区域战略观点揭示了美洲、欧洲、中东、非洲和亚太地区的差异如何影响生物模拟的采用、监管合规性和伙伴关係策略。

区域趋势影响着生物模拟技术的应用、伙伴关係以及监管参与的优先事项，而这些差异又会影响策略和营运选择。在美洲，成熟的製药业、强大的风险投资生态系统以及集中的计算技术专长正在推动整合模拟方法的快速应用。该地区的机构致力于扩展内部能力、整合云端原生工作流程，并使类比输出符合美国食品药物管理局 (FDA) 的预期。相较之下，欧洲、中东和非洲的监管环境和创新环境各不相同，学术联盟、区域性合约研究机构 (CRO) 以及泛欧倡议之间的合作影响着这些地区的应用模式。优先事项包括协调不同司法管辖区的验证标准，以及利用官民合作关係推动方法论的发展。

深入了解推动可靠、可审计和可互通的生物模拟结果的软体专业化、服务整合和伙伴关係策略的关键企业级见解。

生物模拟生态系统中的领先机构已展现出独特的价值创造方式，包括平台专业化、整合服务模式或结合专业知识和运算规模的策略伙伴关係。一些公司专注于针对特定领域量身定制的先进软体功能，例如先进的PBPK和PK/PD建模套件，并结合严格的检验框架和强大的监管合作伙伴关係。另一些公司则采用平台策略，整合分子建模、毒性预测和测试设计工具，建构一致的工作流程，从而减少药物发现和开发团队之间的摩擦。同时，还有一些公司提供基于合约的建模和模拟服务，专注于卓越服务，并为寻求外包复杂模拟的客户提供灵活的专业知识和快速的计划交货。

领导者运用切实可行的建议，将生物模拟能力转化为可重复、符合监管规定且可在营运上可扩展的程序，从而获得策略优势。

产业领导者必须将生物模拟的潜力转化为可衡量的营运改进，方法是将管治、技术和人才与可重复性和可解释性相结合。首先，要建立清晰的检验和文件标准，以反映监管预期和内部审计需求。这将有助于在临床、监管和商业相关人员相关者之间建立信任，并在将模拟作为关键「执行/不执行」决策依据时缩短决策流程。其次，采用优先考虑容器化、云端原生环境和完善的版本控製文件的部署架构，以确保跨团队和跨地域的可移植性和可重复性。这些技术设计选择将减少对特定硬体供应链的依赖，并简化跨境协作。

透过高度透明和严谨的调查方法，结合一手访谈、技术文献综述和跨案例整合，我们获得了实用的见解。

本研究整合了初步访谈、专家咨询以及对方法论文献的全面回顾，以确保结论是基于检验的实践和相关人员的观点。主要资讯来源包括对建模人员、临床开发负责人、监管专家和采购负责人的结构化访谈，重点关注应用驱动因素、检验实践、采购优先事项和整合挑战。二次分析则利用同行评审的论文、监管指导资料和技术白皮书，全面检验了有关建模技术、验证实践和监管验收标准的说法。

检验、管治和互通性技术的协同作用将最终决定谁能实现生物模拟的策略潜力。

生物模拟正处于一个关键的转折点，技术能力、监管认可和组织准备程度在此交汇，决定哪些相关人员能够将建模潜力转化为切实的竞争优势。这个结论整合了许多关键主题，例如：稳健的检验和文件的重要性；建立灵活的部署架构以降低供应链和政策变动风险的必要性；以及将交付模式与特定应用需求相匹配的策略价值。此外，该结论还强调，成功部署不仅取决于演算法和运算资源的复杂程度，还取决于管治、培训和跨职能协作。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物模拟市场：依产品/服务分类

  • 服务
    • 合约服务
    • 内部服务
  • 软体
    • 分子建模模拟软体
    • PBPK建模模拟软体
    • PK/PD建模模拟软体
    • 毒性预测软体
    • 检测和设计软体

第九章：生物模拟市场：依产品模式划分

  • 自有车型
  • 订阅模式

第十章：生物模拟市场：依应用领域划分

  • 药物研发
    • 临床试验
    • 临床前试验
  • 药物发现
    • 先导化合物的鑑定与优化
    • 目标识别与检验

第十一章：生物模拟市场：依最终用户划分

  • 受託研究机构
  • 製药和生物技术公司
  • 监管机构
  • 研究机构

第十二章：生物模拟市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：生物模拟市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：生物模拟市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国生物模拟市场

第十六章：中国的生物模拟市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced Chemistry Development, Inc.
  • Aitia
  • Allucent
  • Biomed Simulation, Inc.
  • BioSimulation Consulting Inc.
  • Cadence Design Systems, Inc.
  • Cell Works Group, Inc.
  • Certara, Inc.
  • Chemical Computing Group ULC
  • Crystal Pharmatech Co., Ltd.
  • Cytel Inc.
  • Dassault Systemes SE
  • ICON PLC
  • In Silico Biosciences, Inc.
  • INOSIM Software GmbH
  • Instem PLC
  • Model Vitals
  • Physiomics PLC
  • Quotient Sciences Limited
  • Resolution Medical
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • Thermo Fisher Scientific Inc.
  • VeriSIM Life
  • VIRTUALMAN
  • Yokogawa Electric Corporation
Product Code: MRR-2D64BA93AB17

The Biosimulation Market was valued at USD 3.89 billion in 2025 and is projected to grow to USD 4.15 billion in 2026, with a CAGR of 6.61%, reaching USD 6.09 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.89 billion
Estimated Year [2026] USD 4.15 billion
Forecast Year [2032] USD 6.09 billion
CAGR (%) 6.61%

A clear and strategic introduction that positions biosimulation as an indispensable cross-functional capability driving translational decisions, regulatory engagement, and operational alignment

Biosimulation has evolved from a specialized research tool into a foundational capability that underpins decision-making across drug discovery, development, and regulatory interactions. This introduction situates biosimulation within the broader innovation ecosystem, identifying how computational modeling, simulation platforms, contract service structures, and organizational delivery models collectively shape translational workflows. It emphasizes the convergence of algorithmic advances, expanded biological datasets, and cloud-enabled compute as catalysts that have amplified biosimulation relevance for stakeholders from bench scientists to regulatory reviewers.

The narrative also clarifies the strategic tensions organizations face as they integrate biosimulation: how to balance in-house capability building against outsourcing, how to select software stacks that align with intended applications such as molecular modeling or PBPK, and how to structure talent and governance to sustain reproducible results. By framing these choices in operational and regulatory terms, the introduction readies decision-makers to interpret subsequent insights through the lens of practical adoption, investment prioritization, and cross-functional coordination.

A comprehensive exploration of how technological, regulatory, and delivery model shifts are reshaping biosimulation practices, partnerships, and organizational value creation

The biosimulation landscape has undergone transformative shifts that extend beyond incremental technical improvements to touch organizational models, regulatory approaches, and collaborative ecosystems. Advances in molecular modeling, physiologically based pharmacokinetic (PBPK) simulation, and PK/PD frameworks are now complemented by more advanced toxicity prediction algorithms and trial design simulation tools, producing a layered toolkit that supports both discovery- and development-stage activities. At the same time, service delivery options have diversified: offerings span contract-based engagements that provide scale and specialized expertise as well as in-house services that preserve institutional knowledge and strategic control over proprietary models.

This change has been reinforced by evolving regulatory expectations that increasingly recognize model-informed evidence as a complement to traditional experimental data. Consequently, stakeholders have had to adapt their validation strategies, documentation practices, and cross-disciplinary communication protocols to ensure that simulations are interpretable and decision-grade. Additionally, the rise of subscription-based software delivery alongside ownership models has altered procurement and lifecycle planning, making software interoperability, data governance, and reproducibility central concerns. These combined shifts are reshaping how projects are scoped, how teams are structured, and how value is realized from biosimulation investments, prompting leaders to rethink partnerships, talent strategies, and governance frameworks in order to capture the potential of computational science.

An evidence-based assessment of how tariff dynamics through 2025 influence biosimulation supply chains, compute strategies, and cross-border collaborations without speculative forecasting

Tariff actions and trade policy adjustments can have cascading effects on the biosimulation ecosystem through their influence on supply chains for hardware, cloud compute costs, software licensing flows, and cross-border service delivery arrangements. In assessing cumulative impacts through 2025, it is important to recognize how tariffs intersect with procurement cycles for high-performance computing equipment and specialized instrumentation that support large-scale simulations, as well as how they affect the cost structure of multinational collaborations and outsourced services.

Practically speaking, organizations that rely on hardware imports or cross-border software maintenance may experience increased complexity in vendor negotiations and total cost of ownership considerations. Development teams engaged in cross-jurisdictional collaboration must also contend with altered timelines when hardware lead times lengthen or when software updates are constrained by licensing distribution changes. In response, many stakeholders have prioritized sourcing flexibility, diversified supplier networks, and stronger contractual protections to hedge against policy-driven volatility. Moreover, because biosimulation workflows often integrate both proprietary and third-party software components, teams have placed new emphasis on software portability and cloud-native deployment strategies to reduce exposure to physical supply-chain disruptions.

Regulatory submissions and validation activities are similarly affected insofar as they depend on reproducible execution environments and documented toolchains. Increased emphasis on environment standardization-through containerization, versioned repositories, and stronger audit trails-has emerged as a mitigation strategy that helps preserve scientific integrity even when external inputs are subject to trade-related uncertainty. Ultimately, the cumulative effect of tariff-related dynamics encourages greater resilience in procurement, technology architecture, and governance, prompting organizations to embed contingency planning into their biosimulation roadmaps.

High-resolution segmentation insights revealing how offering, delivery model, application focus, and end-user context determine biosimulation value and adoption pathways

Segmentation analysis reveals differentiated needs and value drivers across offerings, delivery models, applications, and end users, each demanding tailored strategic responses. When considering solutions by offering, the landscape separates into Services and Software, with Services encompassing both contract engagements and in-house teams that deliver bespoke modeling expertise and results. Software offerings diverge into specialized domains including molecular modeling and simulation, PBPK modeling and simulation, PK/PD modeling and simulation, toxicity prediction, and trial design tools, each serving distinct stages of the discovery and development continuum and requiring unique validation and integration approaches.

Delivery model segmentation contrasts ownership-oriented acquisitions with subscription-based arrangements, shaping governance, upgrade pathways, and capital versus operating expense profiles. In application terms, biosimulation supports both drug development and drug discovery activities. Drug development applications subdivide into clinical trials and preclinical testing; preclinical testing further targets ADME/Tox and PK/PD questions that inform candidate progression. Drug discovery applications concentrate on lead identification and optimization alongside target identification and validation workstreams that accelerate early decision gates. End-user segmentation captures the diversity of institutional actors that adopt biosimulation, including contract research organizations that provide outsourced expertise, pharmaceutical and biotechnology companies that integrate simulations into internal pipelines, regulatory authorities that increasingly require transparent model documentation, and research institutes that drive methodological innovation and foundational science.

Taken together, these segmentation dimensions suggest that a one-size-fits-all approach will not yield optimal outcomes. Instead, effective strategies require combining the right software capabilities with an appropriate delivery model while aligning the solution to specific application needs and the institutional context of the end user. Transitioning from pilot projects to routine use depends on governance structures that span data management, validation protocols, and cross-functional training, ensuring that the chosen segmentation configuration delivers reproducible and decision-grade insights.

Regional strategic perspectives that illuminate how Americas, EMEA, and Asia-Pacific differences shape biosimulation adoption, regulatory alignment, and partnership strategies

Regional dynamics shape priorities for biosimulation deployment, partnerships, and regulatory engagement, and these distinctions inform strategy and operational choices. In the Americas, a mature pharmaceutical industry, a robust venture ecosystem, and concentrated centers of computational expertise have driven rapid adoption of integrated simulation approaches; organizations here focus on scaling internal capabilities, integrating cloud-native workflows, and aligning simulation outputs with FDA expectations. By contrast, Europe, the Middle East, and Africa present a heterogeneous regulatory and innovation landscape where collaboration across academic consortia, regionally focused contract research organizations, and pan-European initiatives influences adoption patterns; priorities include harmonizing validation standards across jurisdictions and leveraging public-private partnerships to advance method development.

In the Asia-Pacific region, rapid expansion of clinical development activity, growing domestic biotech sectors, and significant investments in computational infrastructure have accelerated interest in biosimulation as a competitive differentiator. Organizations in this region often emphasize speed to proof-of-concept and cost-efficient access to modeling expertise, while also navigating diverse regulatory frameworks that are themselves evolving to accommodate model-informed approaches. Across all regions, a common theme emerges: successful implementation requires tailoring deployment strategies to local supplier ecosystems, regulatory expectations, and talent availability, while maintaining interoperability and reproducibility that enable multinational program continuity.

Key company-level insights into software specialization, service integration, and partnership strategies that drive credible, auditable, and interoperable biosimulation outcomes

Leading organizations in the biosimulation ecosystem demonstrate distinct approaches to value creation, whether through platform specialization, integrated service models, or strategic partnerships that combine domain expertise with computational scale. Some companies prioritize deep domain-specific software capabilities-such as advanced PBPK or PK/PD modeling suites-paired with rigorous validation frameworks and strong regulatory engagement. Others adopt platform strategies that integrate molecular modeling, toxicity prediction, and trial design tools into cohesive workflows that reduce friction between discovery and development teams. A parallel set of firms focuses on service excellence, offering contract-based modeling and simulation engagements that provide flexible expertise and rapid project delivery for clients that prefer to outsource complex simulations.

Across these approaches, successful companies invest in interoperability, API-driven integrations, and standardized data schemas to facilitate cross-tool workflows and reproducible results. They also emphasize transparent model documentation, reproducible execution environments, and continuous validation processes to meet the scrutiny of internal stakeholders and regulatory reviewers alike. Strategic partnerships-linking software vendors with contract research organizations, cloud providers, and academic groups-have become a common mechanism to combine capabilities at scale while managing risk. For buyers and collaborators, the implication is clear: evaluate partners not only on the sophistication of their models but on their ability to deliver validated, auditable outcomes that integrate seamlessly into existing development and regulatory processes.

Actionable recommendations for leaders to convert biosimulation capability into reproducible, regulatory-ready, and operationally scalable programs that deliver strategic advantage

Industry leaders must translate biosimulation potential into measurable operational improvements by aligning governance, technology, and talent around reproducibility and interpretability. First, establish clear validation and documentation standards that mirror regulatory expectations and internal audit needs; this builds trust across clinical, regulatory, and commercial stakeholders and shortens decision timelines when simulations are used to inform key go/no-go moments. Second, adopt deployment architectures that prioritize containerized, cloud-native environments and well-documented version control to ensure portability and repeatability across teams and sites. These technical design choices reduce dependency on specific hardware supply chains and simplify cross-border collaboration.

Third, tailor sourcing strategies to organizational priorities: consider in-house capability development for core, strategic modeling tasks while leveraging contract services for episodic or highly specialized needs. Fourth, invest in cross-functional education to ensure that modelers, clinicians, statisticians, and regulatory liaisons share a common vocabulary and appreciation for the constraints and assumptions embedded in simulations. Fifth, structure vendor engagements to include interoperability commitments, data access provisions, and validation support to avoid lock-in and to accelerate integration. Finally, embed continuous improvement loops that capture lessons from regulatory interactions, post-implementation reviews, and project retrospectives to refine model libraries, standard operating procedures, and training curricula, thereby accelerating institutional learning and operational maturity.

A transparent and rigorous research methodology combining primary interviews, technical literature review, and cross-case synthesis to ground findings in real-world practices

This research synthesized primary interviews, expert consultations, and a comprehensive review of methodological literature to ensure that conclusions rest on verifiable practices and stakeholder perspectives. Primary inputs included structured interviews with modelers, clinical development leaders, regulatory specialists, and procurement representatives; these conversations focused on adoption drivers, validation practices, procurement preferences, and integration challenges. Secondary analysis drew on peer-reviewed publications, regulatory guidance documents, and technical white papers to triangulate claims regarding modeling approaches, validation practices, and regulatory acceptance criteria.

Analytical methods emphasized qualitative pattern recognition and cross-case synthesis to surface consistent operational themes. Case studies were selected to illustrate successful integration pathways and mitigation strategies for supply-chain or policy-related disruptions. Throughout, the methodology prioritized transparency: assumptions underlying analytic judgments are documented, and efforts were made to capture diversity across offering types, delivery models, applications, and end users. Where appropriate, sensitivity analyses of process variations were used to highlight trade-offs between in-house investment and outsourced capabilities, enabling readers to map recommendations to their organizational contexts.

A decisive conclusion synthesizing how validation, governance, and interoperable technologies together determine who will realize biosimulation's strategic potential

Biosimulation stands at a pivotal juncture where technological capability, regulatory acceptance, and organizational readiness converge to determine which stakeholders will convert modeling potential into tangible competitive advantage. This conclusion synthesizes key themes: the importance of robust validation and documentation, the need for flexible deployment architectures that reduce exposure to supply-chain and policy volatility, and the strategic value of aligning delivery models with application-specific requirements. Moreover, it emphasizes that successful adoption is as much about governance, training, and cross-functional alignment as it is about the sophistication of algorithms or computational resources.

Looking ahead, organizations that invest in reproducible environments, clear validation standards, and interoperable toolchains will be best positioned to leverage biosimulation for accelerated decision-making and regulatory engagement. By integrating these elements into coherent roadmaps and procurement strategies, leaders can unlock the practical benefits of biosimulation while managing risk and preserving institutional knowledge. The cumulative insight is straightforward: technical excellence must be paired with governance and operational design to translate simulation outputs into trusted inputs for critical R&D and regulatory decisions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biosimulation Market, by Offering

  • 8.1. Services
    • 8.1.1. Contract Services
    • 8.1.2. In-House Services
  • 8.2. Software
    • 8.2.1. Molecular Modeling & Simulation Software
    • 8.2.2. PBPK Modeling & Simulation Software
    • 8.2.3. PK/PD Modeling & Simulation Software
    • 8.2.4. Toxicity Prediction Software
    • 8.2.5. Trial Design Software

9. Biosimulation Market, by Delivery Model

  • 9.1. Ownership Models
  • 9.2. Subscription Models

10. Biosimulation Market, by Application

  • 10.1. Drug Development
    • 10.1.1. Clinical Trials
    • 10.1.2. Preclinical Testing
  • 10.2. Drug Discovery
    • 10.2.1. Lead Identification & Optimization
    • 10.2.2. Target Identification & Validation

11. Biosimulation Market, by End-User

  • 11.1. Contract Research Organizations
  • 11.2. Pharmaceutical & Biotechnology Companies
  • 11.3. Regulatory Authorities
  • 11.4. Research Institutes

12. Biosimulation Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Biosimulation Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Biosimulation Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Biosimulation Market

16. China Biosimulation Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Advanced Chemistry Development, Inc.
  • 17.6. Aitia
  • 17.7. Allucent
  • 17.8. Biomed Simulation, Inc.
  • 17.9. BioSimulation Consulting Inc.
  • 17.10. Cadence Design Systems, Inc.
  • 17.11. Cell Works Group, Inc.
  • 17.12. Certara, Inc.
  • 17.13. Chemical Computing Group ULC
  • 17.14. Crystal Pharmatech Co., Ltd.
  • 17.15. Cytel Inc.
  • 17.16. Dassault Systemes SE
  • 17.17. ICON PLC
  • 17.18. In Silico Biosciences, Inc.
  • 17.19. INOSIM Software GmbH
  • 17.20. Instem PLC
  • 17.21. Model Vitals
  • 17.22. Physiomics PLC
  • 17.23. Quotient Sciences Limited
  • 17.24. Resolution Medical
  • 17.25. Schrodinger, Inc.
  • 17.26. Simulations Plus, Inc.
  • 17.27. Thermo Fisher Scientific Inc.
  • 17.28. VeriSIM Life
  • 17.29. VIRTUALMAN
  • 17.30. Yokogawa Electric Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOSIMULATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOSIMULATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BIOSIMULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BIOSIMULATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BIOSIMULATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BIOSIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 159. GCC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 161. GCC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 163. GCC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 185. G7 BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. G7 BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 188. G7 BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 190. G7 BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 195. NATO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 197. NATO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 199. NATO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 200. NATO BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES BIOSIMULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA BIOSIMULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)